The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.
Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Meet The Startup That Makes Quitting Cigarettes, Vaping And Zyn Cool
New York-based Jones just raised $10 million to expand its nicotine lozenge company in the stodgy, $3 billion smoking cessation market.
Investing25d
Hims and Hers stock falls on Novo Nordisk’s pharmacy launch
Investing.com -- Shares of Hims and Hers (NYSE:HIMS) fell 3% amidst news of Novo Nordisk (NYSE:NVO) introducing NovoCare Pharmacy, which directly impacts the competitive landscape by offering FDA ...
Yahoo Finance22d
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
Hims & Hers has bet big on prescribing compounded versions of these drugs, including by buying its own compounding pharmacy in September. The FDA has allowed pharmacies to make compounded versions ...